Solitons and vortices in ultracold fermionic gases

We investigate the possibilities of generation of solitons and vortices in a degenerate gas of neutral fermionic atoms. In analogy with, already experimentally demonstrated, technique applied to gaseous Bose-Einstein condensate we propose the phase engineering of a Fermi gas as a practical route to excited states with solitons and vortices. We stress that solitons and vortices appear even in a noninteracting fermionic gas. For solitons, in a system with sufficiently large number of fermions and appropriate trap configuration, the Pauli blocking acts as the interaction between particles.Comment: 4 pages, 5 figures many new result

Pathophysiological concepts of functional dyspepsia and irritable bowel syndrome future pharmacotherapy

The functional gastrointestinal diseases (FGIDs) are often noticed disturbances. Functional dyspepsja (FD) is the most frequent FGID of the upper part of the gastrointestinal tract while irritable bowel syndrome (IBS) occurs in the lower gastrointestinal part. Both clinical entities are characterized by rich symptomatology and the patern of the diagnostic guidelines. Recognition and the classification of FGIDs are difficult, consisting in exclusion of all possible organic disorders and subordinating on the predominant symptom basis to most appropriate class, acording to Rome III classification. The present FGIDs pharmacotherapy is limited mostly to the symptomatical treatment and it is based on medicines conventionally used in various gastrointestinal organic illnesses (antisecretory, gastroprotective agents, antidiarrhoeal and laxative drugs). Some of them which seem to diminish visceral hypersensitivity acting via serotonin receptors are also used, including 5-HT4 agonists and 5-HT3 antagonists. Many investigations over the new causal acting medicines last at present, which would be able to abolish the main pathophysiological FD and IBS mechanisms: visceral hypersensitivity and both myoelectrical and dysmotility phenomena. Thus, new pharmacological agents influencing opioid, purinergic, NMDA, CCK-A, or NK receptors are studied. The article is the mini-review, representing classification and the outline of the FGIDs pathogenesis, the present concepts of their pharmacological treatment and the future perspectives of pharmacoherapy with the use of new, interfering into key pathomechanisms drugs

Neuroendocrine activation as a target of modern chronic heart failure pharmacotherapy

At present, a constant progress in pathophysiology understanding and treatment of the chronic heart failure (CHF) is arising. The current CHF pharmacotherapy is complex, involving factors affecting the reninangiotensin- aldosterone system (RAAS), β-blockers, diuretics and vasodilatators. There are also significant efforts to introduce in CHF pharmacology novel therapeutic strategies, based on the other neurohormonal mechanisms activated in CHF. They include vasopressin receptor antagonists (VRA; vaptans), endothelin receptor antagonists (ERA; sentans), agents relating to the natriuretic peptides system (neutral endopeptidase inhibitors; NEPI and vasopeptidase inhibitors; VPI) and anticytokines agents (anti TNF-α immunoglobulin or TNF-α scavenger receptor; Etanercept). In this article we briefly describe the modern approach to CHF systemic treatment

Rola receptorów NMDA w patofizjologii i farmakoterapii wybranych chorób układu nerwowego

Glutaminian jest podstawowym neuroprzekaźnikiem pobudzającym, który działa na receptory NMDA. Związek ten jest współodpowiedzialny za regulowanie wielu ważnych fizjologicznych funkcji, wliczając w to uczenie się, pamięć i zachowanie. Nadmiar glutaminianu i nadaktywność receptorów NMDARs wywołuje patologiczne zmiany. Zjawisko neurotoksyczności zależnej od glutaminianu bierze udział w patogenezie wielu zaburzeń neurologicznych. Artykuł pokrótce opisuje rolę glutaminianu w patofizjologii udaru niedokrwiennego mózgu, wybranych chorób neurodegeneracyjnych i schizofrenii oraz omawia obecne i potencjalne znaczenie leków działających na receptory glutaminergiczne w neuropsychofarmakologii.Glutamate is the basic excitatory neurotransmitter acting via N-methyl-D-aspartate receptors (NMDARs). It co-regulates many important physiological functions, including learning, memory, and behaviour. An excess of glutamate, as well as NMDAR over-activity, produce pathological effects. Glutamate-related neurotoxicity is involved in the pathogenesis of many neurological conditions. This article briefly describes the role of the glutamate system in the pathophysiology of brain ischemia, selected neurodegenerative disorders, and schizophrenia. It also reviews the current and potential future status of agents targeting NMDARs in neuropsychopharmacology

Ultracold dipolar gases - a challenge for experiments and theory

We present a review of recent results concerning the physics of ultracold trapped dipolar gases. In particular, we discuss the Bose-Einstein condensation for dipolar Bose gases and the BCS transition for dipolar Fermi gases. In both cases we stress the dominant role of the trap geometry in determining the properties of the system. We present also results concerning bosonic dipolar gases in optical lattices and the possibility of obtaining variety of different quantum phases in such case. Finally, we analyze various possible routes towards achieving ultracold dipolar gases.Comment: This paper is based on the lecture given by M. Lewenstein at the Nobel Symposium ''Coherence and Condensation in Quantum Systems'', Gothesburg, 4-7.12.200